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Abstract: Although numerous studies have tried to elucidate the best
dialysis modality in end-stage renal disease patients with diabetes,
results were inconsistent and varied with the baseline characteristics
of patients. Furthermore, none of the previous studies on diabetic
dialysis patients accounted for the impact of glycemic control. We
explored whether glycemic control had modifying effect on mortality
between hemodialysis (HD) and peritoneal dialysis (PD) in incident
dialysis patients with diabetes.
A total of 902 diabetic patients who started dialysis between August
2008 and December 2013 were included from a nationwide prospective
cohort in Korea. Based on the interaction analysis between hemoglobinD, PhD, Chul Wo hD,
hin-Wook Kang, MD, PhD
according to dialysis modalities were ascertained in each glycemic
control group after propensity score matching.
During a median follow-up duration of 28 months, the relative risk
of death was significantly lower in PD compared with HD in the whole
cohort and unmatched patients (whole cohort, hazard ratio [HR]¼ 0.65,
95% confidence interval [CI]¼ 0.47–0.90, P¼ 0.01; patients with
available HbA1c [n¼ 773], HR¼ 0.64, 95% CI¼ 0.46–0.91,
P¼ 0.01). In the good glycemic control group, there was a significant
survival advantage of PD (HbA1c <8.0%, HR¼ 0.59, 95% CI¼ 0.37–
0.94, P¼ 0.03). However, there was no significant difference in survival
rates between PD and HD in the poor glycemic control group (HbA1c
8.0%, HR¼ 1.21, 95% CI¼ 0.46–2.76, P¼ 0.80).
This study demonstrated that the degree of glycemic control modi-
fied the mortality risk between dialysis modalities, suggesting that
glycemic control might partly contribute to better survival of PD in
incident dialysis patients with diabetes.
(Medicine 95(11):e3118)
Abbreviations: ADA = American Diabetes Association, ESA =
erythropoiesis-stimulating agent, ESRD = end-stage renal disease,
HbA1c = hemoglobin A1c, HD = hemodialysis, hs-CRP = high-
sensitivity C-reactive protein, PD = peritoneal dialysis, PS =
propensity score, RRF = residual renal function.
INTRODUCTION
D iabetes mellitus is the leading cause of end-stage renaldisease (ESRD) worldwide,1 and the number of diabetic
patients who commence dialysis therapy is constantly increas-
ing.2,3 Therefore, nephrologists are confronted with the problem
of deciding which dialysis modality should be recommended to
these patients in clinical practice. Although dialysis modality is
usually determined based on a number of factors, including the
patient’s clinical condition, socioeconomic status, patient’s or
physician’s preference, and the practice pattern of the institu-
tion, several other problems, such as vascular access and
peritoneal membrane permeability, should be considered before
making a decision for ESRD patients with diabetes mellitus.2 In
addition, patient survival rates in hemodialysis (HD) and per-
itoneal dialysis (PD) are another issue to consider. To date,
numerous previous studies have compared differences in the
survival rates between diabetic HD and PD patients, but theistent.4–18 Heterogeneity of the study
lysis duration, and difference in statisti-
might contribute to these discrepant
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findings among previous studies.2,5,13,18,19 Recently, in this
point of view, the European Renal Best Practice Diabetes
Guideline Development Group proposed that there was a lack
of evidence in favor or against a particular dialysis modality as
the first choice in ESRD patients with diabetes.18
The survival advantage of one dialysis modality over
another has been found to vary according to the presence of
diabetes.4,7,10,12,13 However, none of the previous studies on
diabetic dialysis patients accounted for the impact of glycemic
control, which is known to be closely associated with clinical
outcomes in diabetic patients.20–22 In this study, we hypothes-
ized that glycemic control might have an impact on better
clinical outcomes of one dialysis modality over another in
dialysis patients with diabetes. In contrast to most prior studies
in which only baseline demographic characteristics and comor-
bid diseases were adjusted for,4,6,7,14,17 various previously
demonstrated independent prognostic factors in dialysis
patients, such as high-sensitivity C-reactive protein (hs-CRP),
residual renal function (RRF), and hemoglobin A1c (HbA1c),
were included in the final analysis. In result, we attempted to
clarify the impact of glycemic control on the association
between dialysis modality and patient survival in incident
dialysis patients with diabetes.
METHODS
Ethical Statements
This study was carried out in accordance with the Declara-
tion of Helsinki, and the study protocol was approved by the
Lee et alInstitutional Review Board at each participating hospital’s
Clinical Trial Centre. All patients provided their written
informed consent before entering the study.
FIGURE 1. Flow diagram of patients. Among 1163 incident dialysis p
whole cohort after excluding 261 patients who failed to maintain dialy
HbA1c <8.0% or 8.0%, then PS matching was performed in each gly
and 36 matched pairs, respectively. HbA1c¼hemoglobin A1c, PS¼pr
2 | www.md-journal.comStudy Design and Subjects
All diabetic ESRD patients who started HD or PD between
August 1, 2008 and September 30, 2013 at 36 centers of the
Clinical Research Center for ESRD (CRC for ESRD) in Korea
were initially screened for this study. This study was part of a
nationwide multicenter joint network prospective cohort study
on ESRD patients in Korea designed to improve survival rates
and quality of life and to draw up effective treatment guidelines
(clinicaltrial.gov NCT00931970). Patients younger than 18
years, with a history of kidney transplantation before dialysis
therapy, with underlying active malignancy or acute infection,
or who were expected to survive <3 months were excluded
before the initial screening. Among 2035 incident dialysis
patients, diabetes mellitus was diagnosed in 1163 patients based
on diagnostic criteria of the American Diabetes Association
(ADA).23 After excluding 261 patients who failed to maintain
dialysis for >3 months, 902 patients were included in the final
analysis as the whole cohort. To evaluate the impact of glycemic
control, 773 patients were included after excluding 129 patients
whose mean HbA1c levels during the first 6 months were not
available (Figure 1).
Data Collection and Follow-up
Demographic, clinical and laboratory data were extracted
from the electronic data management system. Demographic and
clinical data including age, sex, height, weight, comorbidities,
smoking history, and body mass index were collected at the time
of study entry. The following laboratory data were measured
Medicine  Volume 95, Number 11, March 2016from fasting blood samples at 3 and 6 months after initiation of
dialysis, and every 6 months thereafter: white blood cell,
hemoglobin, blood urea nitrogen, creatinine, albumin, glucose,
atients with diabetes, 902 patients were primarily analyzed as the
sis for the first 90 days. A total of 773 patients were categorized by
cemic control group. 1:1 Matching resulted in 199 matched pairs
opensity score.
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HbA1c, calcium, phosphorous, and hs-CRP. Blood glucose
concentrations were determined by the hexokinase-UV method,
and HbA1c levels were measured by high-performance liquid
chromatography. RRF was estimated by 24-hour urine collec-
tion. Participants were followed up until September 30, 2015.
All death events were retrieved from the CRC for ESRD
database and were carefully reviewed. Death events were also
confirmed by the Korea National Statistics database. Loss to
follow-up, renal transplantation, or recovery of renal function
after the first 90 days of dialysis initiation was censored at the
end of dialysis treatment.
Statistical Analysis
Statistical analysis was performed using SPSS for Windows
version 20.0 (SPSS Inc, Chicago, IL) and R (R Foundation for
Statistical Computing, Vienna, Austria; www.r-project.org).
Continuous variables were expressed as mean standard devi-
ation or median (interquartile range [IQR]), and categorical
variables were expressed as a number (percentage). To compare
baseline characteristics according to dialysis modality, Student t
test or Mann-WhitneyU test andx2 test were used for continuous
variables and categorical variables, respectively. Modality
change was observed in 37 patients (4.1%; HD to PD in 8 patients
and PD to HD in 29 patients), an intention-to-treat analysis was
adopted rather than an as-treated analysis for survival analysis.
The dialysis modality at day 90 was considered the initial dialysis
modality. Cumulative survival curves were generated by the
Kaplan–Meier method, and between-group survival was com-
pared by a log-rank test. The relative hazard ratio (HR) for
mortality of PD compared with HD was ascertained using Cox
proportional hazard regression models. Violation of the pro-
portional hazard assumption was tested by conducting a visual
examination of the log-minus-log plots. To address our hypoth-
esis whether glycemic control had a modifying impact on patient
survival rates of one dialysis modality over the other, the inter-
action between HbA1c and dialysis modalities were tested. Since
HbA1c levels had an interaction with dialysis modality on survival
rates (P for interaction¼ 0.04), stratified analysis was performed
based on the HbA1c value of 8.0% (<8.0 or 8.0%). The mean
value of HbA1c was used at baseline, 3 months, and 6 months after
dialysis initiation. Because HD and PD were not randomly
assigned, we performed propensity score (PS) matching for
mitigating the confounding effects of different baseline charac-
teristics according to dialysis modalities. PS was calculated by
multivariable logistic regression analysis in each HbA1c group.
All covariates were used for PS matching. Patients were matched
1:1 by PS using a nearest-neighbor matching algorithm. PS
matching yielded 199 matched pairs in HbA1c <8.0% and 36
pairs in HbA1c 8.0%. Supplementary Figure 1, http://
links.lww.com/MD/A804 shows the distribution of PS in the
unmatched and matched groups. To compare baseline character-
istics between two dialysis modalities in the matched group, the
Wilcoxon signed rank test was used for continuous variables and
Medicine  Volume 95, Number 11, March 2016McNemar test was used for categorical variables. Consecutive
survival analysis was performed in each HbA1c group. Two-sided
P values <0.05 were considered statistically significant.
RESULTSBaseline Characteristics
The baseline data of 902 patients and 773 patients with
available HbA1c are shown in Table 1. In the whole cohort
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.(n¼ 902), the mean age was 62.2 11.9 years and 573 patients
(63.5%) were male. HD was the initial modality in 637 patients
(70.6%) and PD was the initial modality in 265 patients
(29.4%). The median value of HbA1c was 6.4% (IQR¼ 5.7–
7.3). In 773 patients who had HbA1c measurement, the initial
modality was HD in 538 patients (69.6%) and PD in 235
patients (30.4%). There was no significant difference in the
proportion of dialysis modality between patients with and
without HbA1c.
Survival Rates According to Dialysis Modality in
the Whole Cohort and Patients With Available
HbA1c
During a median follow-up duration of 28 (IQR¼ 13–41)
months, 191 patients among the whole cohort of 902 patients
(21.2%) died. The crude death rates were 101.1/1000 patient-
years in the HD group and 67.6/1000 patient-years in the PD
group. Kaplan-Meier analysis showed that cumulative patient
survival was significantly worse in HD patients compared with
PD patients (log-rank test, P¼ 0.009) (Figure 2A). The 1-, 2-,
and 5-year patient survival rates were 92.0%, 84.0%, and 59.0%
for HD patients, whereas they were 97.0%, 90.0%, and 65.0%
for PD patients, respectively. In 773 patients whose HbA1c
concentrations were available, Kaplan–Meier curves also
revealed that cumulative survival rates were significantly lower
in HD compared with PD patients (log-rank test, P¼ 0.012)
(Figure 2B). Cox proportional hazard analysis found that PD
was associated with a lower risk of death compared with HD
in not only the whole cohort but also the available HbA1c
group (whole cohort, HR¼ 0.65, 95% confidence interval
[CI]¼ 0.47–0.90, P¼ 0.01; patients with available HbA1c,
HR¼ 0.64, 95% CI¼ 0.46–0.91, P¼ 0.01) (Table 2).
Impact of Glycemic Control on Survival
Advantage of PD Over HD
PS matching resulted in no differences in baseline charac-
teristics between HD and PD in both HbA1c <8.0% (Table 3)
and 8.0% groups (Table 4). Difference in survival rates
between HD and PD varied according to the degree of glycemic
control (Figure 3). The cumulative survival rates were signifi-
cantly lower in HD relative to PD in patients with HbA1c<8.0%
(log-rank test, P¼ 0.021) (Figure 3A). However, there was no
significant difference in the cumulative survival rates between
HD and PD in patients with HbA1c 8.0% (log-rank test,
P¼ 0.770) (Figure 3B). Furthermore, the survival advantage
of PD over HD remained consistent in the good glycemic
control group even after PS was adjusted in the multivariate
model (HbA1c <8.0%, HR¼ 0.59, 95% CI¼ 0.37–0.94,
P¼ 0.03) (Table 2). However, patient survival rates were
comparable between 2 dialysis modalities in the poor glycemic
control group in PS-adjusted model (HbA1c8.0%, HR¼ 1.21,
95% CI¼ 0.46–2.76, P¼ 0.80) as well as in the crude model
(Table 2).
DISCUSSION
Innumerable studies have demonstrated the survival
advantage of one dialysis modality over another in diabetic
dialysis patients, but the results have been conflicting. In this
study, we demonstrate that PD was significantly associated with
Glycemic Control and Dialysis-related Mortalitydecreased risk of all-cause mortality compared with HD in
Korean incident dialysis patients with diabetes. Moreover, we
found that better patient survival in PD was associated with the
www.md-journal.com | 3
TABLE 1. Baseline Characteristics of Patients With and Without HbA1c
All Patients With HbA1c Patients Without HbA1c
(n¼ 902) (n¼ 773) (n¼ 129) P
Age, y 62.2 11.9 62.2 11.9 61.9 11.9 0.78
Male, n (%) 573 (63.5%) 492 (63.6%) 81 (62.8%) 0.84
Hemodialysis, n (%) 637 (70.6%) 538 (69.6%) 99 (76.7%) 0.12
Modified CCI 6.2 2.2 6.1 2.1 6.4 2.3 0.24
Comorbid disease, n (%)
CAD 151 (16.7%) 130 (16.8%) 21 (16.3%) 0.9
PAD 92 (10.2%) 81 (10.5%) 11 (8.5%) 0.64
CVA 95 (10.5%) 80 (10.3%) 15 (11.6%) 0.64
CHF 119 (13.2%) 109 (14.1%) 10 (7.8%) 0.05
Smoker, n (%) 431 (47.8%) 379 (49.0%) 52 (40.3%) 0.07
Systolic blood pressure, mmHg 142.6 22.3 142.5 22.5 143.1 21.5 0.80
Diastolic blood pressure, mmHg 76.4 13.1 76.5 13.0 75.9 13.2 0.66
BMI, kg/m2 23.4 3.3 23.4 3.4 23.5 2.9 0.76
HbA1c (%) — 6.4 (5.7–7.3) — —
White blood cell, 103/mL 7.4 3.3 7.4 3.3 7.1 3.2 0.32
Hemoglobin, g/L 90 15 90 16 91 15 0.41
Blood urea nitrogen, mmol/L 27.7 12.5 28.2 12.4 25.0 13.2 0.01
Creatinine, mmol/L 689.5 291.7 689.5 282.9 680.7 300.6 0.76
Albumin, g/L 32 6 32 6 31 5 0.09
Calcium, mmol/L 2.0 0.2 2.0 0.2 2.0 0.2 0.56
Phosphorous, mmol/L 1.7 0.6 1.7 0.6 1.7 0.6 0.49
hs-CRP, mg/L

0.39 (0.12–1.43) 0.39 (0.12–1.33) 0.72 (0.20–2.48) 0.01
ESA use, n (%) 615 (68.2%) 552 (71.4%) 63 (50.0%) <0.001
RRF, mL/min/1.73m2 8.2 4.4 8.2 4.4 8.3 4.7 0.9
Data are expressed as mean standard deviation, median (interquartile range), or number of patients (%). BMI¼ body mass index, CAD¼
coronary artery disease, CCI¼Charlson comorbidity index, CHF¼ congestive heart failure, CVA¼ cerebrovascular accident, ESA¼ erythropoiesis-
stimulating agent, HbA1c¼ hemoglobin A1c, hs-CRP¼ high-sensitivity C-reactive protein, PAD¼ peripheral artery disease, RRF¼ residual renal
function.
A1
Lee et al Medicine  Volume 95, Number 11, March 2016degree of glycemic control. PD patients had a survival
advantage in the good glycemic control group, but not in the
poor glycemic control group.

hs-CRP values were available in 70 patients of patients without HbEven though the choice of dialysis modality is a critical
issue, it remains an unsettled question in diabetic dialysis
patients. Among a number of factors, patient survival is one
FIGURE 2. Kaplan–Meier analysis of all-causemortality according to d
patients who had available HbA1c. Patients treated with HD showed
whole cohort (log-rank test, P¼0.009) and in 773 patients (log-ran
PD¼peritoneal dialysis.
4 | www.md-journal.comimportant concern to consider before determining the dialysis
modality. Several previous studies showed that PD patients had
a lower risk of death in the first 1 to 2 years after starting dialysis
c.therapy,2,4,6,9,15,16,19,24 which was attributed to preserved RRF
in these patients.11,25 However, this issue was not fully eval-
uated because of lack of RRF data in previous studies.4,6,16,24 In
ialysis modality in the (A) whole cohort of 902 patients and (B) 773
significantly higher all-cause mortality than those with PD in the
k test, P¼0.012). HbA1c¼hemoglobin A1c, HD¼hemodialysis,
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. HRs of Mortality for Peritoneal Dialysis ComparedWith Hemodialysis in theWhole Cohort, Unmatched Available HbA1c
Group, and PS-matched Group
HR (95% CI) P
Whole cohort (n¼ 902) Crude 0.65 (0.47–0.90) 0.01
Unmatched group (n¼ 773) Crude 0.64 (0.46–0.91) 0.01
PS matched group
HbA1c <8.0% (n¼ 398) Crude 0.59 (0.37–0.93) 0.02
Adjusted for PS 0.59 (0.37–0.94) 0.03
HbA1c 8.0% (n¼ 72) Crude 1.43 (0.47–2.81) 0.77
o, P
Medicine  Volume 95, Number 11, March 2016 Glycemic Control and Dialysis-related Mortalityour study, RRF was not significantly associated with dialysis
modality in terms of patient survival (P for interaction¼ 0.24).
Moreover, there were no significant differences in mortality
between HD and PD patients in both the lower and higher RRF
group (data not shown). Therefore, we surmised that the survi-
val advantage of our PD patients was not linked to RRF. Instead,
these findings were more likely attributed to overall improve-
Adjusted for PS
CI¼ confidence interval, HbA1c¼ hemoglobin A1c, HR¼ hazard ratiment of PD outcomes, which was recently observed in many
cohort studies.2,7,14,19,26,27 Mehrotra et al26 demonstrated that a
progressive decline in mortality risk was observed in PD
TABLE 3. Baseline Characteristics for Unmatched and Propensity
Unmatched
HD PD
(n¼ 460) (n¼ 199)
Age, y 64.1 11.7 59.0 11.6
Male, n (%) 287 (62.4%) 137 (68.8%)
Modified CCI 6.2 2.1 5.9 2.3
Comorbid disease, n (%)
CAD 77 (16.7%) 39 (19.6%)
PAD 44 (9.6%) 22 (11.1%)
CVA 52 (11.3%) 19 (9.5%)
CHF 54 (11.7%) 34 (17.1%)
Smoker, n (%) 221 (45.9%) 116 (58.3%)
SBP, mmHg 144.4 22.9 139.7 21.7
DBP, mmHg 75.5 13.5 78.6 12.8
BMI, kg/m2 23.4 3.5 23.5 3.3
HbA1c (%) 6.2 (5.6–6.8) 6.3 (5.6–6.9)
White blood cell, 103/mL 7.4 3.7 7.3 2.5
Hemoglobin, g/L 28.8 5.4 32.8 5.4
BUN, mmol/L 80.7 35.7 77.0 34.3
Creatinine, mmol/L 698 3.4 707 292
Albumin, g/L 33 6 33 6
Calcium, mmol/L 2.0 0.2 2.0 0.2
Phosphorous, mmol/L 1.7 0.6 1.8 0.6
hs-CRP, mg/L 0.39 (0.14–1.50) 0.39 (0.11–1.24
ESA use, n (%) 348 (75.7%) 131 (65.8%)
RRF, mL/min/1.73m2 8.0 4.3 8.1 3.9
Data are expressed as mean standard deviation, median (interquartile ra
urea nitrogen, CAD¼ coronary artery disease, CCI¼Charlson comorbidity i
DBP¼ diastolic blood pressure, ESA¼ erythropoiesis-stimulating agent, H
C-reactive protein, PAD¼ peripheral artery disease, PD¼ peritoneal dialysi
blood pressure.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.patients between the earlier (1996–1998) and more recent
(2002–2004) cohorts. Similarly, a study from the Taiwan
showed that diabetic PD patients had worse survival than
diabetic HD patients in the 1997 to 2001 cohort. However,
the survival difference did not exist in the 2002 to 2006
cohort.14 Although the exact mechanism for this salutary
change in PD patient survival is not clear, application of
1.21 (0.46–2.76) 0.80
S¼ propensity score.quality-improvement programs in PD, individualization of
PD prescription, and reduced risk of PD-related infectious
complications have been proposed as reasonable candidates.19
Score-Matched Groups in Patients With HbA1c <8.0%
PS-Matched
P
HD PD
P(n¼ 199) (n¼ 199)
<0.001 59.5 12.3 59.0 11.6 0.71
0.07 136 (68.3%) 137 (68.8%) 0.91
0.24 6.0 2.3 5.9 2.3 0.86
0.22 43 (21.6%) 39 (19.6%) 0.62
0.32 22 (11.1%) 22 (11.1%) 1.0
0.30 17 (8.5%) 19 (9.5%) 0.73
0.04 32 (16.1%) 34 (17.1%) 0.79
0.002 102 (51.3%) 116 (58.3%) 0.16
0.01 139.2 22.4 139.7 21.7 0.83
0.01 76.8 14.4 78.6 12.8 0.20
0.81 23.5 3.6 23.5 3.3 0.92
0.34 6.2 (5.6–6.9) 6.3 (5.6–6.9) 0.45
0.55 7.7 3.6 7.3 2.5 0.12
<0.001 32.8 5.4 32.8 5.4 0.92
0.22 77.2 35.4 77.0 34.3 0.95
0.73 698 292 707 292 0.79
0.94 33 6 33 6 0.71
0.50 2.0 0.2 2.0 0.2 0.79
0.51 5.4 0.6 5.5 0.6 0.69
) 0.04 0.39 (0.10–1.33) 0.39 (0.11–1.24) 0.80
0.007 137 (68.8%) 131 (65.8%) 0.52
0.79 8.1 3.9 8.1 3.9 0.92
nge), or number of patients (%). BMI¼ body mass index, BUN¼ blood
ndex, CHF¼ congestive heart failure, CVA¼ cerebrovascular accident,
bA1c¼ hemoglobin A1c, HD¼ hemodialysis, hs-CRP¼ high-sensitivity
s, PS¼ propensity score, RRF¼ residual renal function, SBP¼ systolic
www.md-journal.com | 5
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FIGURE 3. Kaplan–Meier analysis of all-causemortality according to dialysismodality in the (A) PS-matched good glycemic control group
(HbA1c <8.0%) and (B) PS-matched poor glycemic control group (HbA1c 8.0%). Cumulative survival rates were significantly lower in
(n¼
rol
.
Medicine  Volume 95, Number 11, March 2016 Glycemic Control and Dialysis-related MortalityIt is noteworthy that the survival advantage of PD was
altered by the degree of glycemic control in diabetic patients
starting dialysis therapy. The survival advantage of one dialysis
modality over the other varied according to the presence of
diabetes.4,7,10,12,13 However, so far, no study has explored the
impact of glycemic control, which is closely related with
clinical outcomes in diabetic patients,20–22 on the difference
in patient survival between the two dialysis modalities in
diabetic dialysis patients. In our study, the better survival of
PD patients was observed only in patients with HbA1c <8.0%,
suggesting that the survival benefit of PD was robust in the good
glycemic control group. The mechanism by which glycemic
control exerts an impact on the mortality of PD relative to HD in
diabetic ESRD patients can somewhat be explained by perito-
neal damage from hyperglycemia and adherence to treatment.
Since PD patients are exposed to a large amount of glucose
absorbed from the dialysate,28 continuous exposure to dialysate
might worsen glycemic control and induce peritoneal damage in
diabetic patients. Indeed, high peritoneal membrane transport
characteristic along with increased protein permeability is more
commonly accompanied in diabetic PD patients than nondia-
betic PD patients.29 Although an objective assessment of per-
itoneal damage according to the degree of glycemic control was
not performed, we inferred that the detrimental effect of poor
glycemic control may accelerate peritoneal damage and late
diabetic complications. This, in turn, lessened the survival
benefit of PD in patients with HbA1c 8.0%. Meanwhile, since
PD is a home-based modality, a patient’s adherence to treatment
and their ability to follow instructions are crucial to maintaining
therapy. Adherence to therapy was revealed to be associated
with the risk of hospitalization and mortality in dialysis
patients;29 in other words, compliant patients had a lower
mortality risk. Moreover, a recent study showed that patients
starting PD had increased risks of hospitalization and perito-
nitis, especially in the early period.30 These findings suggest
that adaptation of self-care education is important to reduce
mortality risk.30 Taken together, we suggest that patients in the
patients on HD compared with PD in good glycemic control group
difference in survival rates between HD an PD in poor glycemic cont
HD¼hemodialysis, PD¼peritoneal dialysis, PS¼propensity scoregood glycemic control groups were more compliant, and thus
were able to achieve self-care, which may partly contribute to
the survival advantage of PD.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.The present study has several limitations. First, even
though the PS matching method was used to overcome limita-
tions of nonrandom allocation to dialysis modality, residual
confounding effect cannot be totally excluded. It was difficult to
examine whether the indication bias of dialysis modality selec-
tion exerted any influence on clinical outcomes. However, to
date, most studies included only demographics and comorbid-
ities.4,6,7,14,17 In contrast, various dialysis-related prognostic
factors, including biochemical variables such as hemoglobin,
albumin, calcium, phosphorous, and hs-CRP, as well as RRF
were used in this study for PS matching to mitigate confounding
effect. Second, as HbA1c values at baseline, 3 months, and 6
months after dialysis initiation were not available in 129
patients, these patients were excluded from the final analysis
of PS matching. But there were no significant differences
between patients with and without mean HbA1c levels except
the use of erythropoiesis-stimulating agent (ESA). Third, shor-
tened erythrocyte survival and ESA use can discredit HbA1c as a
marker of glycemic control in dialysis patients. To overcome
this limitation, hemoglobin concentrations and ESA use were
included in PS calculation and it was revealed that there were no
significant differences in hemoglobin levels and ESA use
between HD and PD after PS matching. Recent evidence
indicated that HbA1c had modest-to-strong correlations with
serum glucose, glycated albumin, and serum fructosamine, and
these correlations were similar between HD and PD patients.31
Glycated albumin and fructosamine have been known to be
impervious to anemia than HbA1c,
31 but unfortunately, these
surrogates were not available in our cohort. Fourth, the HbA1c
cutoff value of 8.0% used to stratify patients into good and poor
glycemic control groups was relatively arbitrary. However, as
our subjects were incident dialysis patients and the mean value
of HbA1c at dialysis initiation and during the first 6 months was
used, HbA1c <8.0% was defined as the good glycemic control
group according to the ADA guideline for patients with
advanced micro or macrovascular complications (stage 3 or
worse chronic kidney disease).32 Fifth, as this study included
398, log-rank test, P¼0.021). However, there was no significant
group (n¼72, log-rank test, P¼0.770). HbA1c¼hemoglobin A1c,only Korean incident dialysis patients, results may not be
generalized to other populations. Primary outcome in the pre-
sent study was relatively small compared with those in Western
www.md-journal.com | 7
ESRD patients. We surmised that the difference may be attrib-
uted to disparate ethnicities, as the mortality rates of our patients
were comparable with those of Japanese patients.33 Lastly, the
follow-up duration was relatively short. Notwithstanding these
limitations, the present study has distinct strengths. The hetero-
geneity of the study population has been indicated as a possible
reason for discrepant findings among previous studies. Accord-
ing to a recent systematic review of 25 eligible studies by the
European Renal Best Practice Diabetes Guideline Development
Group, no study included only diabetic patients18; the pro-
portion of diabetic patients ranged from 9%12 to 61%.16 On
the contrary, we included only incident dialysis patients with
diabetes to focus the impact of glycemic control in these
patients and to preserve sufficient statistical power. Finally,
the present study enrolled nationally distributed subjects from
private clinics to tertiary hospitals between 2008 and 2013,
suggesting that the results of this study on our nationwide
contemporary cohort could be more helpful to provide evidence
for deciding optimal dialysis modality for Korean diabetic
dialysis patients in the present era.
In conclusion, the overall patient survival of PD was
significantly higher compared with that of HD in incident
dialysis patients with diabetes. In addition, better patient survi-
val with PD was influenced by the degree of glycemic control.
Survival advantage of PD patients was consistent only in the
good glycemic control group. These findings suggest that
glycemic control may partly contribute to better survival of
PD in Korean incident dialysis patients with diabetes. Never-
theless, further well-designed randomized controlled studies are
required to delineate the causal relationship between glycemic
control and dialysis modality-related mortality in these patients.
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